Magnetic Resonance Imaging and Spectroscopy Means and Methods Thereof
OwnerRachel Katz-Brullinventor
Life of this patent
Estimating the term…
Abstract
The present invention discloses neurochemical agents and biochemical agents for human or mammalian neuro- and body-metabolic imaging, comprising chemicals involved in neuronal or glial function, neuromodulatory processes in the brain of said human or mammalian, vascular function, or organ specific metabolic processes; said neurochemical and biochemical agents are labeled with stable isotopes selected from a group including carbon-13, nitrogen-15, deuterium, fluorine-19 or a combination thereof in predetermined positions, so as to enhance the detectability of the agents and their metabolic successors.
Claims13
1-40. (canceled)
High T1 neurochemical and biochemical contrast agents (HTNCs) for imaging metabolic processes and activities in the brain or body of either human or otherwise mammalian (patient);
- said HTNCs comprising chemicals involved in neuronal or brain function or neuromodulatory processes in the brain of said patient, vascular function, or organ specific metabolic processes;
- said HTNCs are labeled with stable isotopes selected from a group consisting of deuterium, carbon-13, nitrogen-15, fluorine-19 (2H, 13C, 15N, 19F) or a combination thereof in predetermined positions, so as to enhance the detectability of both the agents and their metabolic successors.
A method of detecting spatial and temporal distribution of High T1 neurochemical and biochemical contrast agents (HTNCs) and their metabolic/catabolic products within the brain or body of either human or mammalian (patient);
- said method comprising at least one of the following steps:
- a. ex vivo polarizing one or more HTNCs involved in neuronal or brain function, or neuromodulatory processes in the brain of said patient, vascular function, or organ specific metabolic processes;
- said HTNCs are labeled with stable isotopes selected from a group consisting of deuterium, carbon-13, nitrogen-15, fluorine-19 (2H, 13C, 15N, 19F) or a combination thereof in predetermined positions;
- b. administrating a human, or otherwise a mammalian patient said polarized HTNCs;
- and,
- c. monitoring the distribution of said HTNCs and their metabolic successors in the brain or body of said patients by means of magnetic resonance spectroscopy and imaging the same;
- said monitoring applied after at least one step of administrating of said polarized HTNCs, in at least one time point after said administration.
Dependencies are inferred from the claim text.